PD-L1 status in breast cancer

Франк, Г. А.; Кузнецова, О А; Завалишина, Л Э; Andreeva, Yu Yu; Olyushina, E M; Vinogradov, I Yu; Vinogradov, M.; Куликов, Е. П.; Шомова, М В

doi:10.17116/patol2019810213

Cited by 4 publications

(2 citation statements)

References 13 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our work, we analyzed the immunohistochemical expression of PD-L1 using the 22C3 antibody clone, which was cleared by the FDA for the evaluation of PD-L1 immunoexpression in TNBC patients receiving the PD-1 checkpoint inhibitor pembrolizumab. 69 Of note, a recent study which utilized three different antibody clones of PD-L1 in IDC, including the IHC 22C3 clone, has showed similar staining patterns between the three primary antibodies, suggesting that the expression level is not necessarily affected by the antibody clone used. 70 Second, the variation can be attributed to different cut-off values for evaluating PD-L1 positivity.…”

Section: Discussionmentioning

confidence: 91%

PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy

Alhesa

Awad

Bloukh

et al. 2022

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Objectives: To investigate the expression of programmed death-ligand 1 (PD-L1) in breast cancer in association with incomplete pathological response (PR) to neoadjuvant chemotherapy (NAC). Methods PD-L1 expression was evaluated using immunohistochemistry in post-operative, post-NAC samples of 60 patients ( n = 60) diagnosed with breast invasive ductal carcinoma with incomplete PR to NAC, including 31 matched pre-NAC and post-NAC samples ( n = 31). PD-L1 protein expression was assessed using three scoring approaches, including the tumor proportion score (TPS), the immune cell score (ICS), and the combined tumor and immune cell score (combined positive score, CPS) with a 1% cut-off. Results In the post-operative, post-NAC samples ( n = 60), positive expression rate of PD-L1 was observed in 18.3% (11/60) of cases by TPS, 31.7% (19/60) by ICS, and 25% (15/60) by CPS. In matched samples, positive expression rate of PD-L1 was observed in 19.3% (6/31) of patients by TPS, 51.6% (16/31) by ICS, and 19.3% (6/31) by CPS in pre-NAC specimens, while it was observed in 22.6% (7/31) of matched post-NAC samples by TPS, 22.6% (7/31) by ICS, and 19.3% (6/31) by CPS. In the matched samples, there was a significant decrease in PD-L1 immunoexpression using ICS in post-NAC specimens (McNemar’s, p = 0.020), while no significant differences were found using TPS and CPS between pre- and post-NAC samples ( p = 1.000, p = 0.617; respectively). PD-L1 immunoexpression determined by TPS or CPS was only significantly associated with ER status ( p = 0.022, p = 0.021; respectively), but not with other clinicopathological variables. We could not establish a correlation between PD-L1 expression and the overall survival rate ( p > 0.05). There were no significant differences in the tumor infiltrating lymphocytes count between the paired pre- and post-NAC samples ( t = 0.581, p = 0.563 or Wilcoxon’s Signed Rank test; z = -0.625, p = 0.529). Conclusion Our findings indicate that PD-L1 protein expression in infiltrating immune cells was significantly reduced in breast tumors that developed incomplete PR following the exposure to NAC.

show abstract

Section: Discussionmentioning

confidence: 91%

PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy

Alhesa

Awad

Bloukh

et al. 2022

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…PD-L1-статуса опухоли в целом, быть неодинаковой в первичной и рецидивной опухолях, множественных опухолях, метастазах [19].…”

Section: обзорная статья | Reviewunclassified

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review

et al. 2023

View full text Add to dashboard Cite

Gastric cancer is one of the most common oncological diseases at the present time, so research in this area is very significant and relevant. Immunological checkpoint inhibitors have previously demonstrated their effectiveness and safety in various solid tumors, however, with regard to stomach cancer, to date, ambiguous results have been presented. Tumor cells express programmed death ligand 1 (PD-L1), which binds to its programmed death receptor 1 (PD-1). Immune defense plays a key role in the initiation and progression of the disease. Understanding the regulatory mechanism of PD-L1 in gastric cancer can lead to significant progress in immunotherapy, as well as contribute to the adequate selection of patients treated with checkpoint inhibitors. In the review, we conducted an in-depth study of PD-L1 expression and regulatory immunosuppressive mechanisms in gastric cancer and methods for assessing PD-L1 status, and also studied the results of current clinical trials in which inhibitors of immunological control points were considered in combination with and without chemotherapy for this oncopathology.

show abstract